Receptor tyrosine kinases as targets for anticancer drugs

Trends in Molecular Medicine

Volumn 8, Issue 1, 2002, Pages 17-23

  Zwick, Esther ^a   Bange, Johannes ^a   Ullrich, Axel ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; PARACRINE SIGNALING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MODELS, GENETIC; MUTATION; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR CELLS, CULTURED;

EID: 0036139884     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(01)02217-1     Document Type: Review

References (56)

1. Signal transduction by receptors with tyrosine kinase activity
2. RTK mutations and human syndromes when good receptors turn bad
3. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
4. Pathologic findings from the national surgical adjuvant breast and bowel project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer
5. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
6. The role of EGFR in solid tumors and implications for therapy
7. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
8. Evidence for a role of EGF receptor in the progression of human lung carcinoma
9. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification
10. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
11. FGF receptor mutations: Dimerization syndromes, cell growth suppression, and animal models
12. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
13. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
14. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers
15. Ret in human development and oncogenesis
16. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines
17. Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas
18. The mutationally activated met receptor mediates motility and metastasis
19. Synthesis of messenger RNAs for transforming growth factors α und β and the epidermal growth factor by human tumors
20. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation
21. Epidermal growth factor-related peptides and their receptors in human malignancies
22. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer
23. Mrna expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells
24. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
25. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma
26. Downmodulation of TGF-α protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells
27. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF
28. Epidermal growth factor receptor signal transactivation
29. Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission
30. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor
31. Therapeutic application of anti-growth factor receptor antibodies
32. The development of monoclonal antibodies for the therapy of cancer
33. Recombinant antibody constructs in cancer therapy
34. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
35. Molecular targets for breast cancer therapy and prevention
36. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
37. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
38. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice
39. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
40. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
41. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
42. Signaling antibodies in cancer therapy
43. Protein tyrosine kinase inhibitors as novel therapeutic agents
44. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: Role as anticancer agents
45. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
46. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
47. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
48. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
49. Editorial. Quick success for cancer kinase treatment
50. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy
51. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
52. Development of inhibitors for protein tyrosine kinases
53. Targeted toxins
54. Targeting diphteria toxin to growth factor receptors
55. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas
56. Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I antisense oligonucleotides